The Next Evolution of Immunotherapies

Alpine Immune Sciences

Our MissionWe're Hiring!

A Unique Approach
to Immunology

Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies. Formed in 2014, we have created and advanced multiple product candidates into clinical trials for inflammatory/autoimmune diseases and cancer, formed collaborations with world-class partners, and built a robust development pipeline.

Our scientific platform consists of unique protein engineering strategies, including the directed evolution of immune proteins into novel, multi-targeted therapeutics. With such differentiated candidates, we hope to improve outcomes in patients with cancer and severe inflammatory and autoimmune diseases.

Join us in the discovery and development of next-generation immunotherapies.

Current job openingsLearn more about Alpine

Alpine’s Pipeline

We have a diverse pipeline. For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filingscorporate presentations, and scientific publications.

Acazicolcept (ALPN-101)

Dual CD28/ICOS Costimulation Antagonist
Autoimmune Diseases

Davoceticept (ALPN-202)

Conditional (PD-L1-dependent) CD28 Costimulator and Dual Checkpoint (PD-L1/CTLA-4) Inhibitor
Oncology

ALPN-303

Dual BAFF/APRIL B cell cytokine antagonist
Autoimmune Diseases
See our complete pipeline

Latest News

AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the oral presentation of results from the dose-escalation portion of NEON-1…

READ MORE

Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications

Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced a publication in Nature Communications on the preclinical development of davoceticept…

READ MORE

Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting

Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that Alpine will host a virtual investor event on April 12th, 2022…

READ MORE